Real-world efficacy and safety of mobocertinib in EGFR exon 20 insertion-mutated lung cancer

por Kian, Waleed, Christopoulos, Petros, Remilah, Areen A., Levison, Esther, Dudnik, Elizabeth, Shalata, Walid, Krayim, Bilal, Marei, Ranin, Yakobson, Alexander, Faehling, Martin, Kahala, Dolev, Sara Granot, Inbal, Levitas, Dina, Peled, Nir, Roisman, Laila C.
Publicado 2022

Osimertinib in advanced EGFR-mutant lung adenocarcinoma with asymptomatic brain metastases: an open-label, 3-arm, phase II pilot study

por Peled, Nir, Kian, Waleed, Inbar, Edna, Goldstein, Iris M, Zemel, Melanie, Rotem, Ofer, Rozenblum, Anna B, Nechushtan, Hovav, Dudnik, Elizabeth, Levin, Daniel, Zer, Alona, Keren-Rosenberg, Shoshana, Yust-Katz, Shlomit, Fuchs, Vered, Remilah, Areen A, Shelef, Ilan, Roisman, Laila C
Publicado 2021